



Description générale

Ritonavir is recommended for use in combination with other protease inhibitors as a pharmacological booster in the prevention and treatment of HIV/AIDS, and not as an antiretroviral in its own right.

| | |
|----------------------------|---|
| INN | Ritonavir |
| Codes ATC | J05AE03 |
| Type de médicament | Chemical agent |
| Historique des statuts LME | Ajouté pour la première fois en 2002 (TRS 914) pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |
| Wikipédia | Ritonavir  |
| DrugBank | Ritonavir  |

Recommandations

Section Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

